Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-infected Patients

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy and safety of switching from Retrovir to Tenofovir or Abacavir in HIV-infected patients

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aarhus University Hospital
• Treatments: Abacavir; Dideoxynucleosides; Tenofovir

Criteria

Inclusion Criteria:

• HIV-infection with undetectable viral load

• Antiretroviral treatment including Retrovir for more than three months

• If fertile female: Negative pregnancy test and use of safe contraception

• Negative HBs-antigen titer

Exclusion Criteria:

• Prior treatment with abacavir or tenofovir

• Resistance towards abacavir or tenofovir

• Tissue type HLA-B5701

• Renal disease

• Diabetes Mellitus

• Osteoporosis

• Pregnant or lactating subjects

• Intravenous drug abuse

• Hypersensitivity towards drugs or active ingredient used

• ALAT > 5 times upper normal level

• Current alcohol or substance abuse judged by the Investigator to potentially interfere with subject compliance